Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.6.5 has been added, replacing the previous v3.6.4. This indicates a new revision of the page, without changes to the substantive study content.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a newer build of the page. This change is a backend/version update and does not modify the study details or user-visible content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3. This reflects a minor update to the page's versioning, not a change to visible content.SummaryDifference0.1%

- Check44 days agoChange DetectedA new revision tag Revision: v3.6.2 was added, replacing the previous v3.6.0 tag.SummaryDifference0.0%

- Check51 days agoChange DetectedPublications section added with a PubMed-cited article related to the study, and a note that such publications are automatically populated from PubMed.SummaryDifference0.2%

- Check58 days agoChange DetectedEnrollment status updated to indicate recruitment is closed, signaling that the study will no longer seek new participants.SummaryDifference0.5%

Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.